Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: Investigating differential effects among statins

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2477-2487

  Bergheanu, Sandrin C ^a   Reijmers, Theo ^b   Zwinderman, Aeilko H ^c   Bobeldijk, Ivana ^d   Ramaker, Raymond ^d   Liem, An Ho ^e   van der Greef, Jan ^b,d   Hankemeier, Thomas ^b   Jukema, J Wouter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d TNO   (Netherlands)

^e Oosterschelde Hospital   (Netherlands)

Author keywords

Atorvastatin; Cardiovascular risk; Phosphatidylcholines; Rosuvastatin; Sphingomyelins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; ROSUVASTATIN; SPHINGOMYELIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPIDOMICS; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME;

CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MASS SPECTROMETRY; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 53349173867     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802321709     Document Type: Article

References (37)

1. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61:1835-81
2. Schaefer EJ, McNamara JR, Tayler T, et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002; 90:689-96
3. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28
4. Schuster H. Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40mg doses in dyslipidemic patients. Cardiology 2003;99:126-39
5. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123-31
6. Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006;151:975-9
7. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY I) study. Am Heart J 2004;147:705-13
8. Leiter LA, Rosenson RS, Stein E, et al. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007;194:154-64
9. Bergheanu SC, Van Tol A, Dallinga-Thie GM, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007;23:2235-40
10. Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin 2005;21:1865-74
11. Dietzen DJ, Page KL, Tetz1off TA, et al. inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine. Arterioscler Thromb Vasc Biol 2007;27:690-6
12. Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005;112:93-102
13. Pelat M, Dessy C, Massion P, et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480-6
14. Van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics 2006;7:1087-94
15. Van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005;4:961-7
16. Van der Greef J, Martin S, Juhasz P, et al. The art and practice of systems biology in medicine: mapping patterns of relationships. J Proteome Res 2007;6:1540-59
17. Van der Greef J, Davidov E, Verheij ER, et al. Metabolic profiling: its role in biomarker discovery and gene function analysis. In: Harrigan GG, Goodacre R, eds. The role of Metabolomics in Systems Biology, a New Vision for Drug Discovery and Development. Boston: Kluwer Academic Publishing, 2003.
18. Huck SW. Analyses of variance with repeated measures. In: Reading Statistics and Research, Chapter 14. Boston: Pearson Education, 2008.
19. Jackson JE. A User's Guide to Principal Components. New York: John Wiley, 1991
20. Brereton RG. Chemometrics Data Analysis for the Laboratory and Chemical Plant. Chichester. UK: John Wiley, 2007
21. Vandengiste BGM, Massart DL, Buydens LMC, et al. Handbook of Chemometrics and Qualimetrics. Amsterdam: Elsevier, 1998
22. Park TS, Panek RL, Rekhter MD, et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006;189:264-72
23. Nelson JC, Jiang XC, Tabas I, et al. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006;163:903-12
24. Jiang XC, Paultre F, Pearson TA, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000;20:2614-18
25. Schlitt A, Blankenberg S, Yan D, et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) 2006;3:5
26. Oestvang J, Bonnefont-Rousselot D, Ninio E, et al. Modification of LDL with human secretory phospholipase A(2) or sphingomyelinase promotes its arachidonic acid-releasing propensity. J Lipid Res 2004;45:831-8
27. Kleemann R, Princen HM, Emeis JJ et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-74
28. Arimoto I, Saito H, Kawashima Y, et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998;39:143-51
29. Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithincholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996;271:19152-8
30. Puri V, Jefferson JR, Singh RD, et al. Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage. J Biol Chem 2003;278:20961-70
31. Worgall TS, Juliano RA, Seo T, et al. Ceramide synthesis correlates with the posttranscriptional regulation of the sterol-regulatory element-binding protein. Arterioscler Thromb Vasc Biol 2004;24:943-8
32. Smith EB. Intimal and medial lipids in human aortas. Lancet 1960;1:799-803
33. Noel C, Marcel YL, Davignon J. Plasma phospholipids in the different types of primary hyperlipoproteinemia. J Lab Clin Med 1972;79:611-21
34. Schissel SL, Jiang X, Tweedie-Hardman J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J Biol Chem 1998;273:2738-46
35. Jeong T, Schissel SL, Tabas I, et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998;101:905-12
36. Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823-32
37. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006;1:e97